Latest Headlines
CATEGORY
-
2024-09-18Biosyngen’s first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial Phase I trial data debut at ESMO 2024 Annual CongressBarcelona, Spain – September 13-17, 2024 – The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchersREAD MORE -
2024-08-13Biosyngen’s BRG01 Receives FDA Approval for Phase II Clinical TrialBiosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial. This marks the first cell therapy to enter Phase lI trials in both the U.S. and China for the treatment of reREAD MORE -
2024-08-01Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune TherapyBiosyngen has announced a strategic collaboration with Singapore's Agency for Science, Technology and Research (A*STAR) to enhance autoimmune therapy. The partnership was signed during the 14th Meeting of the Singapore-Guangdong Collaboration Council, held at China-Singapore Guangzhou Knowledge CityREAD MORE -
2024-07-15Biosyngen’s BRG01 enters Phase II clinical trial, a first-in-kind autologous EBV-Specific CAR-T Therapy for Solid Tumors on Recurrent/Metastatic Nasopharyngeal CarcinomaBiosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration(NMPA) in China has approved the initiation of a pivotal Phase ll clinical trial evaluatingREAD MORE -
2024-04-09Biosyngen reached a significant milestone in the Clinical Trial for BRG01, all patients for Phase 1 have completed dosing in less than a yearBiosyngen, an emerging biotech in the domain of immune cell therapy, pioneering multiple first-in-class products tailored for the treatment of various cancers such as nasopharyngeal cancer, liver cancer, digestive tract tumors, lung cancer, and other solid tumors. The company has secured eight cliniREAD MORE -
2024-02-01Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver CancerFebruary 1, 2024 - Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.READ MORE
